Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBPNASDAQ:DAWNNASDAQ:PHARNASDAQ:TOCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$20.40-1.1%$19.18$15.47▼$36.37$697.95M1.47182,678 shs360,630 shsDAWNDay One Biopharmaceuticals$6.27$7.23$6.08▼$16.76$635.54M-1.241.12 million shs1.05 million shsPHARPharming Group$10.43-0.7%$8.77$6.65▼$11.07$709.22M-0.086,477 shs1,290 shsTOCATocagen$8.49+12.9%$32.24$0.42▼$6.77$203.07M0.011.47 million shs18,704 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma-1.11%+5.37%-3.23%-24.64%+2.56%DAWNDay One Biopharmaceuticals0.00%+0.32%-15.73%-49.56%-57.11%PHARPharming Group-0.71%+10.54%+26.06%+16.48%+12.46%TOCATocagen+5.77%-3.96%+9.78%-31.51%+1,153.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVBPArriVent BioPharma0.9724 of 5 stars3.60.00.00.01.90.00.0DAWNDay One Biopharmaceuticals2.6979 of 5 stars4.61.00.00.02.52.50.0PHARPharming Group1.7599 of 5 stars3.53.00.00.00.00.00.6TOCATocagenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.14Buy$39.2992.58% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57387.58% UpsidePHARPharming Group 3.00Buy$30.00187.77% UpsideTOCATocagen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TOCA, AVBP, PHAR, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025AVBPArriVent BioPharmaJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.005/14/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$39.00 ➝ $40.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.003/20/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.003/20/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.003/19/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/14/2025PHARPharming GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$30.00 ➝ $39.003/14/2025PHARPharming GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$37.00 ➝ $37.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A($4.79) per shareN/ADAWNDay One Biopharmaceuticals$161.92M3.92N/AN/A$3.98 per share1.58PHARPharming Group$320.71M2.21$0.11 per share91.82$3.26 per share3.20TOCATocagen$40K5,076.81N/AN/A$0.45 per share18.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$69.33M-$3.77N/AN/AN/AN/A-43.89%-29.67%N/ADAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)PHARPharming Group-$10.55M-$0.20N/A347.50N/A-6.09%-7.65%-3.82%7/30/2025 (Estimated)TOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/ALatest TOCA, AVBP, PHAR, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AVBPArriVent BioPharma-$0.66-$1.90-$1.24-$1.90N/AN/A5/8/2025Q1 2025PHARPharming Group-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million3/13/2025Q4 2024PHARPharming Group$0.07$0.05-$0.02$0.05$76.67 million$92.70 million3/3/2025Q4 2024AVBPArriVent BioPharma-$0.78-$0.60+$0.18-$0.61N/AN/A2/25/2025Q4 2024DAWNDay One Biopharmaceuticals-$0.35-$0.69-$0.34-$0.69$27.11 million$29.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A19.2819.28DAWNDay One BiopharmaceuticalsN/A14.6214.55PHARPharming Group0.413.532.76TOCATocagen1.881.151.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%DAWNDay One Biopharmaceuticals87.95%PHARPharming Group0.03%TOCATocagen21.42%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharmaN/ADAWNDay One Biopharmaceuticals6.20%PHARPharming Group2.07%TOCATocagen10.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4034.21 millionN/AN/ADAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionablePHARPharming Group28068.03 million66.62 millionNot OptionableTOCATocagen7723.92 millionN/ANot OptionableTOCA, AVBP, PHAR, and DAWN HeadlinesRecent News About These CompaniesTocagen plummets on phase 3 data for glioma therapyFebruary 2, 2025 | pharmaphorum.comCelgene hopes device + drug can tackle aggressive brain tumoursSeptember 18, 2024 | pharmaphorum.comForte Biosciences Inc (FBRX)August 7, 2024 | investing.comAnova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM GrantMay 1, 2024 | finance.yahoo.comGlioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.bizMarch 25, 2024 | pharmiweb.comONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline GliomaFebruary 12, 2024 | ascopubs.orgMiami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumorsJanuary 20, 2024 | eurekalert.orgForte Biosciences: Changes In Registrant S Certifying AccountantDecember 12, 2023 | cbonds.comRiskOn International And 3 Other Stocks Under $2 Insiders Are BuyingDecember 11, 2023 | markets.businessinsider.comPrecision and personalized medicine: the leading companies in personalized cancer vaccines revealedNovember 6, 2023 | pharmaceutical-technology.comProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board AppointmentNovember 2, 2023 | finance.yahoo.comFDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma PatientsJuly 26, 2023 | precisionmedicineonline.comGene Therapy Market Report 2023 Provides SWOT Analysis ... - openPRMay 12, 2023 | news.google.comForm DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.comApril 29, 2023 | news.google.comGenomic and transcriptomic analysis of checkpoint blockade ... - Nature.comApril 6, 2023 | news.google.comBelzutifan plus cabozantinib for patients with advanced clear cell ... - The LancetMarch 31, 2023 | news.google.comCurrent drug development and trial designs in neuro-oncology ... - The LancetMarch 28, 2023 | news.google.comCompanion Diagnostics Market is set to experience a significant ... - Digital JournalMarch 27, 2023 | news.google.comOligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital JournalMarch 14, 2023 | news.google.comAnaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital JournalMarch 8, 2023 | news.google.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreBy Sam Quirke | May 14, 2025View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t IgnoreThese Are the Only 6 Stock Stocks in NVIDIA's 13F PortfolioBy Leo Miller | May 22, 2025View These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.By Leo Miller | April 28, 2025View 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?By Leo Miller | May 6, 2025View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?TOCA, AVBP, PHAR, and DAWN Company DescriptionsArriVent BioPharma NASDAQ:AVBP$20.40 -0.23 (-1.11%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.40 0.00 (0.00%) As of 05/23/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Day One Biopharmaceuticals NASDAQ:DAWN$6.27 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$6.30 +0.03 (+0.46%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Pharming Group NASDAQ:PHAR$10.42 -0.08 (-0.71%) Closing price 05/23/2025 03:52 PM EasternExtended Trading$10.42 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Tocagen NASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
